Skip to main content

Table 7 Bispecific/bifunctional antibodies targeting PD-1/PD-L1

From: Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Target

Antibody Product

Company/Authors

Reference

TGF-β × PD-L1

M7824

Merck KGaA

[278]

YM101

Wuhan YZY Biopharma

[279]

SHR-1701

Hengrui Pharmaceuticals

[280]

CTLA-4 × PD-L1

KN046

Alphamab Oncology

[281]

CTLA-4 × PD-1

MGD019

MacroGenics

[282]

MEDI5752

AstraZeneca

[283]

LAG-3 × PD-L1

IBI323

Innovent Biologics

[284]

LAG-3 × PD-1

Tebotelimab

MacroGenics

[285]

TIM-3 × PD-L1

LY3415244

Eli Lilly

[286]

TIGIT×PD-L1

Not given

Novamab Biopharmaceuticals

[287]

4-1BB × PD-L1

MCLA-145

Merus and Incyte

[288]

ABL503

ABL Bio

[289]

PM1003

Biotheus

[290]

CD27 × PD-L1

CDX-527

Celldex Therapeutics

[291]

c-Met×PD-1

Not given

Yuan et. al

[292]

Not given

Hou et. al

[293]

Not given

Wu et. al

[294]

Not given

Sun et. al

[295]

EGFR×PD-L1

Not given

Koopmans et. al

[296]

PD-1 × PD-L1

LY3434172

Eli Lilly

[297]

CD47 × PD-L1

IBI322

Innovent Biologics

[298]